Also, although systemic therapies cause a decrease in inflammatory markers (a decrease compared to the group of untreated patients), their values do not become comparable to those of naïve patients, emphasizing the persistence of background inflammation, despite the treatment. CRP values were also significantly higher in patients with treatment-naive psoriasis (p=0.0001) and psoriasis subjects treated with methotrexate (p=0.016) compared to the control group. The gene discussed is CRP; the disease is psoriasis.